Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

YOU WONT BELIEVE: Pear therapeutics earnings perspective return on capital employed - You Need To See This

According to data from Benzinga Pro, during Q1, Pear Therapeutics's (NASDAQ:PEAR) reported sales totaled $2.75 million. Despite a 62.5% increase in earnings, the company posted a loss of $23.86 million. In Q4, Pear Therapeutics brought in $1.32 million in sales but lost $63.63 million in earnings.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.